



Welcome

Orion Capital Markets Day 2021



Agenda

Theme	Presenter
Introduction	Timo Lappalainen, President & CEO
Creating growth towards 2025 target and beyond	Satu Ahomäki, SVP Commercial Operations
	<i>Discussion with Niclas Lindstedt, VP Animal Health</i>
	Virve Laitinen, SVP Specialty Products
	10 min. BREAK at ~14.15 EEST
	Q&A at 14.25-14.35 EEST
Creating long-term value	Jari Karlson, Chief Financial Officer
	Outi Vaarala, SVP Research & Development
	<i>Discussion with Liisa Hurme, SVP Global Operations</i>
	5 min. BREAK at ~15.35 EEST
	Q&A at 15.40-15.50 EEST
Closing remarks	Timo Lappalainen, President & CEO

Disclaimer

This presentation contains forward-looking statements which involve risks and uncertainty factors. These statements are not based on historical facts but relate to the Company's future activities and performance. They include statements about future strategies and anticipated benefits of these strategies.

These statements are subject to risks and uncertainties. Actual results may differ substantially from those stated in any forward-looking statement. This is due to a number of factors, including the possibility that Orion may decide not to implement these strategies and the possibility that the anticipated benefits of implemented strategies are not achieved. Orion assumes no obligation to update or revise any information included in this presentation.

All the figures in this presentation have been rounded, which is why the total sums of individual figures may differ from the total sums shown.



Gaining growth and creating value

Timo Lappalainen, President & CEO




Disclaimer

This presentation contains forward-looking statements which involve risks and uncertainty factors. These statements are not based on historical facts but relate to the Company's future activities and performance. They include statements about future strategies and anticipated benefits of these strategies.

These statements are subject to risks and uncertainties. Actual results may differ substantially from those stated in any forward-looking statement. This is due to a number of factors, including the possibility that Orion may decide not to implement these strategies and the possibility that the anticipated benefits of implemented strategies are not achieved. Orion assumes no obligation to update or revise any information included in this presentation.

All the figures in this presentation have been rounded, which is why the total sums of individual figures may differ from the total sums shown.

2025 Growth target - key positives and negatives so far



Net sales (continued operations) 2018-2020



Orion's strategic focus areas and targets

Focus Areas



Quality and safety



Strong corporate culture of working together



Productivity and flexibility



Competitive product portfolio



Partnerships

Targets



Growing more rapidly than the growth in the market → EUR 1.5 billion in 2025



Providing new innovative and cost-effective drugs and treatments for patients



Working together to benefit the customer



Continuous improvement of performance in sustainability




Strong development of profitability

Gaining growth, creating value and building the future



The estimated average growth of the pharmaceutical market is 3-6% annually



● Average annual growth 2021-2025

○ Market share in 2025

Europe, TOP 5 = Germany, France, Italy, United Kingdom, Spain

Orion's Sustainability Agenda



Patient safety and ensuring reliable supply of medications



Responsibility for the environment



Responsibility for Orionees



Business ethics and transparency



Orion Corporation Capital Markets Day